期刊文献+

康莱特联合替吉奥治疗老年晚期胃癌疗效观察 被引量:5

下载PDF
导出
摘要 目的探讨康莱特联合替吉奥治疗老年晚期胃癌的疗效和可行性。方法选择老年晚期胃癌患者64例,分为2组,研究组32例予口服替吉奥联合康莱特治疗,对照组32例单纯予替吉奥口服,2个周期后评价疗效。结果 64例患者除对照组1例因重度黏膜炎中途停止治疗外,其余均完成治疗。研究组有效率、临床控制率均高于对照组,患者生活质量以及对化疗的耐受性均明显提高。结论康莱特联合替吉奥治疗老年晚期胃癌疗效确切,不良反应小,患者耐受性好。
出处 《现代中西医结合杂志》 CAS 2012年第30期3374-3376,共3页 Modern Journal of Integrated Traditional Chinese and Western Medicine
  • 相关文献

参考文献10

  • 1周际昌.实用肿瘤内科学[M].2版.北京:人民卫生出版社,2005:92-94.
  • 2金懋林.抗癌新药治疗胃癌进展[M].北京:科学出版社,2000:55-64.
  • 3秦叔逵,龚新雷.晚期胃癌化疗的现状和新进展[J].临床肿瘤学杂志,2006,11(9):641-652. 被引量:268
  • 4Makl-Manino M, Malnino R. Clinical studies of three oral prodrug of 5-fluorouracil ( capecitabine,UFT,S- 1 ) :a review[J]. On- cologist ,2002,7 ( 4 ) :288 - 323.
  • 5Shirasaka T,Tsukuda M ,Inuyama Y ,et al. New oral anti-cancer drug, TS- 1 (S- 1 ) -form bench to clinic[J]. Gan To Kagaku Ryoho, 2001,28 ( 6 ) : 855 - 864.
  • 6刘江华,戚苏明,陈国俊,陆宏国,苏苗.替吉奥胶囊临床研究进展[J].中国现代医生,2008,46(30):62-63. 被引量:32
  • 7白坂哲彦 佃守犬山 夫他新规.经口抗癌剂TS-1(S-1).癌症化学疗法,2001,:855-864.
  • 8Shirasaka T,Shimamato Y,Ohshimo H,et al. Development of a novel- form of an oral 5 -fluorouracil derivative(S- 1 )directed to the po- tentiation of the tumor selective cytot - oxieity of 5 - fliorouracil by two biochemical modulators [ J ]. Anticancer Drugs, 1996,7 ( 5 ) : 548 - 557.
  • 9Koizurni W. S - 1 plus cisplatin versus S - I alone for first - line treatment of advanced gastric cancer. (SPIRITS trial) :a phase III trial[ J]. Lancet Oncol,2008,9 ( 3 ) :215.
  • 10李大鹏.康莱特注射液(KLT)的临床应用[J].中国肿瘤临床,2001,28(4):300-302. 被引量:18

二级参考文献23

  • 1钱军,秦叔逵,梅静峰,陈映霞,邵志坚,何泽明.奥沙利铂联合卡培他滨二线治疗晚期胃癌的临床观察[J].中华肿瘤杂志,2004,26(12):746-748. 被引量:60
  • 2袁泉.羟基脲、替加氟及亚叶酸钙治疗27例晚期鼻咽癌临床观察[J].中国医药导报,2007,4(07Z):54-55. 被引量:14
  • 3[2]Fukushima M,Satake H,Uchida J,et al.Preclinical antitu-mour eficacy of S-1:a new oral form ulation of 5-fluorouracilon human tomour xenografts[J].Int J Oncol,1998,13:693.
  • 4Moiseyenko VM,Ajani JA,Tjulandin SA,et al.Final results of a randomized controlled phase Ⅲ trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F)to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC)[ J ].J Clin Onc,Proc Am Soc Clin Oncol,2005,23:Abstract 4002.
  • 5Al-Batran S,Hartmann J,Probst S,et al.A randomized phase Ⅲ trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil,leucovorin and oxaliplatin (FLO) versus fluorouracil,leucovorin and cisplatin (FLP)[J].J Clin Onc,Proc Am Soc Clin Oncol,2006,24:Abstract 4016.
  • 6Bugat R.Irinotecan in the treatment of gastric cancer[J].Ann Oncol,2003,14(Suppl 2):37 -40.
  • 7Bouche O,Raoul JL,Bonnetain F,et al.Randomized multicenter phase Ⅱ trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2),LV5FU2 plus cisplatin,or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer:a Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803[ J].J Clin Oncol,2004,22 (21):4319-4328.
  • 8Fazio N,Zampino G,Nol F,et al.Irinotecan combined with in fusional 5-fluorouracil and folinic acid (folfiri) in patients with metastatic gastric cancer resistant to cisplatin-containing chemo therapy[J].J Clin Onc,Proc Am Soc Clin Oncol,2004,22:Abstract 4146a.
  • 9Peeters M,Van Laethem JL,Baert F,et al.Phase Ⅱ study of irinotecan+ 5FU/FA for patients with previously treated ad vanced gastric cancer[J].J Clin Onc,Proc Am Soc Clin Oncol,2004,22:Abstract 4076a.
  • 10Bamias A,Papamichael D,Syrigos K,et al.Phase Ⅱ study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer[J].J Chemother,2003,15(3):275 -281.

共引文献410

同被引文献52

引证文献5

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部